ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Weak Electromagnetic Fields Can Possibly Stabilize Tumors

September 30, 2011

In Brief: Paul Van Nevel, Director Of NCI Communications, To Retire At Year’s End

November 26, 1999

Race, Age Play Role In Delay Of Surgery For Breast Cancer

December 28, 2007

FDA Approves Herceptin For HER2+ Metastatic Stomach Cancers

October 22, 2010

In Brief: WHI Revises Protocol After Study Finds High Rate Of Endometrial Hyperplasia

January 27, 1995

In Brief: Des Exposed Women Face New Risk: Unfavorable Pregnancies; Hutchinson Labor Election Set

March 21, 1980